DE60311236D1 - 5-(2-hydroxy-3-'1-(3-trifluormethylphenyl)-cycloproplü-propionylamino)-phtalid und verwandte verbindungen mit progesteron-rezeptor-modulierender wirkung zur verwendung bei der fertilitätskontrolle und hormonersatztherapie - Google Patents

5-(2-hydroxy-3-'1-(3-trifluormethylphenyl)-cycloproplü-propionylamino)-phtalid und verwandte verbindungen mit progesteron-rezeptor-modulierender wirkung zur verwendung bei der fertilitätskontrolle und hormonersatztherapie

Info

Publication number
DE60311236D1
DE60311236D1 DE60311236T DE60311236T DE60311236D1 DE 60311236 D1 DE60311236 D1 DE 60311236D1 DE 60311236 T DE60311236 T DE 60311236T DE 60311236 T DE60311236 T DE 60311236T DE 60311236 D1 DE60311236 D1 DE 60311236D1
Authority
DE
Germany
Prior art keywords
hormonary
cycloproplu
phtalide
propionylamino
trifluoromethylphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60311236T
Other languages
English (en)
Other versions
DE60311236T2 (de
Inventor
Norbert Schmees
Manfred Lehmann
Ulrike Fuhrmann
Hans-Peter Muhn
Christa Hegele-Hartung
Michael Klotzbuecher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP02005530A external-priority patent/EP1344776A1/de
Application filed by Schering AG filed Critical Schering AG
Application granted granted Critical
Publication of DE60311236D1 publication Critical patent/DE60311236D1/de
Publication of DE60311236T2 publication Critical patent/DE60311236T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/02—1,2-Oxazines; Hydrogenated 1,2-oxazines
DE60311236T 2002-03-11 2003-03-10 5-(2-hydroxy-3-'1-(3-trifluormethylphenyl)-cycloproplü-propionylamino)-phtalid und verwandte verbindungen mit progesteron-rezeptor-modulierender wirkung zur verwendung bei der fertilitätskontrolle und hormonersatztherapie Expired - Fee Related DE60311236T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US36304402P 2002-03-11 2002-03-11
EP02005530A EP1344776A1 (de) 2002-03-11 2002-03-11 5- 2-Hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino -phtalid- und 6- 2-Hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino -4-methyl-2,3-benzoxazin-1-on-Derivate mit progesteronrezeptor-modulierender Wirkung zur Anwendung in der Empfängnisverhütung, Hormonersatztherapie und zur Behandlung von gynäkologischen Störungen
EP02005530 2002-03-11
US363044P 2002-03-11
PCT/EP2003/002441 WO2003075915A1 (en) 2002-03-11 2003-03-10 5-}2-hydroxy-3-`1-(3-trifluoromethylphenyl)-cyclopropyl!-propionylamino}- phtalide and related compounds with progesterone receptor modulating activity for use in fertility control and hormone replacement therapy

Publications (2)

Publication Number Publication Date
DE60311236D1 true DE60311236D1 (de) 2007-03-08
DE60311236T2 DE60311236T2 (de) 2008-02-14

Family

ID=27806515

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60311236T Expired - Fee Related DE60311236T2 (de) 2002-03-11 2003-03-10 5-(2-hydroxy-3-'1-(3-trifluormethylphenyl)-cycloproplü-propionylamino)-phtalid und verwandte verbindungen mit progesteron-rezeptor-modulierender wirkung zur verwendung bei der fertilitätskontrolle und hormonersatztherapie

Country Status (26)

Country Link
US (1) US7388006B2 (de)
EP (1) EP1482925B1 (de)
JP (1) JP2005526064A (de)
CN (1) CN1652768A (de)
AR (1) AR035904A1 (de)
AU (1) AU2003209720A1 (de)
BR (1) BR0308394A (de)
CA (1) CA2478948A1 (de)
CR (1) CR7490A (de)
DE (1) DE60311236T2 (de)
DK (1) DK1482925T3 (de)
ES (1) ES2280766T3 (de)
HR (1) HRP20040923A2 (de)
IL (1) IL164032A0 (de)
MX (1) MXPA04008881A (de)
NO (1) NO20044279L (de)
NZ (1) NZ535427A (de)
PE (1) PE20040157A1 (de)
PL (1) PL372490A1 (de)
PT (1) PT1482925E (de)
RS (1) RS89504A (de)
RU (1) RU2314299C2 (de)
TW (1) TW200307674A (de)
UA (1) UA78027C2 (de)
UY (1) UY27715A1 (de)
WO (1) WO2003075915A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004062182B4 (de) * 2004-12-20 2007-06-06 Bayer Schering Pharma Ag Transdermales Pflaster mit Progesteron A-Spezifische Liganden (PRASL) als Wirkstoff
US20070015689A1 (en) * 2005-06-23 2007-01-18 Alza Corporation Complexation of metal ions with polypeptides
US7408060B2 (en) 2005-06-24 2008-08-05 Schering Ag Nonsteroidal progesterone receptor modulators
DE102005030294A1 (de) * 2005-06-24 2007-01-04 Schering Ag Nichtsteroidale Progesteronrezeptor-Modulatoren
BRPI0619519A2 (pt) * 2005-12-09 2011-10-04 Hoffmann La Roche compostos de propionamida como agentes antiinflamatórios
JP4980366B2 (ja) * 2005-12-09 2012-07-18 エフ．ホフマン−ラ ロシュ アーゲー 抗炎症剤としてのグルココルチコイド受容体モジュレーター
UY30805A1 (es) * 2006-12-21 2008-07-31 Bayer Schering Pharma Ag Moduladores no esteroides de receptores de progesterona
DE102006061913A1 (de) * 2006-12-21 2008-06-26 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
CN101289408B (zh) * 2007-04-18 2013-02-27 中国科学院上海药物研究所 非甾体类孕激素受体调节剂及其制备方法、药物组合物和用途
DE102007032800A1 (de) 2007-07-10 2009-01-15 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
DE102007058747A1 (de) 2007-12-05 2009-06-10 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
US20090170823A1 (en) * 2007-12-20 2009-07-02 Duramed Pharmaceuticals, Inc. Dosage Regimens and Pharmaceutical Compositions and Packages for Emergency Contraception
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP3079668A1 (de) 2013-12-09 2016-10-19 Durect Corporation Pharmazeutisch aktive wirkstoffkomplexe, polymerkomplexe und zusammensetzungen und verfahren damit
KR20170005819A (ko) 2014-05-22 2017-01-16 쎄러퓨틱스엠디, 인코퍼레이티드 천연 복합 호르몬 대체 제형 및 요법
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
JP2019513709A (ja) 2016-04-01 2019-05-30 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． ステロイドホルモン薬学的組成物
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
JP6940626B2 (ja) * 2017-05-10 2021-09-29 ヴェンタナ メディカル システムズ， インク． ｐＨ調整を利用する安定化した２パートヘマトキシリン溶液
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8617653D0 (en) * 1986-07-18 1986-08-28 Ici Plc Amide derivatives
DE19723722A1 (de) * 1997-05-30 1998-12-10 Schering Ag Nichtsteroidale Gestagene
US6245804B1 (en) * 1997-05-30 2001-06-12 Schering Aktiengesellschaft Nonsteroidal gestagens
NO312255B1 (no) * 2000-06-28 2002-04-15 Pgs Reservoir Consultants As Verktöy for gjennomhulling av et langsgående veggparti av et fôringsrör
DE10038639A1 (de) * 2000-07-28 2002-02-21 Schering Ag Nichtsteroidale Entzündungshemmer
AU2002219218A1 (en) * 2000-12-28 2002-07-16 Schering Ag Method for screening for progesterone receptor isoform-specific ligands

Also Published As

Publication number Publication date
DK1482925T3 (da) 2007-05-14
PT1482925E (pt) 2007-04-30
AR035904A1 (es) 2004-07-28
DE60311236T2 (de) 2008-02-14
PL372490A1 (en) 2005-07-25
BR0308394A (pt) 2005-01-25
UY27715A1 (es) 2003-08-29
US7388006B2 (en) 2008-06-17
UA78027C2 (en) 2007-02-15
NZ535427A (en) 2006-08-31
EP1482925A1 (de) 2004-12-08
IL164032A0 (en) 2005-12-18
MXPA04008881A (es) 2004-12-07
JP2005526064A (ja) 2005-09-02
RU2004130430A (ru) 2005-08-10
US20030232824A1 (en) 2003-12-18
NO20044279L (no) 2004-12-08
EP1482925B1 (de) 2007-01-17
HRP20040923A2 (en) 2004-12-31
ES2280766T3 (es) 2007-09-16
CR7490A (es) 2006-02-07
CN1652768A (zh) 2005-08-10
TW200307674A (en) 2003-12-16
RS89504A (en) 2006-10-27
AU2003209720A1 (en) 2003-09-22
CA2478948A1 (en) 2003-09-18
WO2003075915A1 (en) 2003-09-18
RU2314299C2 (ru) 2008-01-10
PE20040157A1 (es) 2004-06-03

Similar Documents

Publication Publication Date Title
DE60311236D1 (de) 5-(2-hydroxy-3-'1-(3-trifluormethylphenyl)-cycloproplü-propionylamino)-phtalid und verwandte verbindungen mit progesteron-rezeptor-modulierender wirkung zur verwendung bei der fertilitätskontrolle und hormonersatztherapie
DE60317677D1 (de) Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung
DE60317630D1 (de) Indol, azaindol und verwandte heterocyclische pyrrolidin-derivate
ATE381334T1 (de) 2,5-substituiertetetrahydroisochinoline zur verwendung als 5-ht6 modulatoren
ATE447570T1 (de) Pyrimidinderivate zur verwendung als vanilloidrezeptorliganden und deren verwendung bei der behandlung von schmerzen
DE50310122D1 (de) 4-substituierte 1-aminocyclohexan-derivate zur verwendung als orl1-rezeptor- und mu-opiat-rezeptor-liganden
DE69602624T2 (de) Instrumentation zur Verwendung in der orthopädischen Chirurgie
ATE542816T1 (de) Azabicycloä3.1.0ühexanderivate und ihre verwendung als modulatoren des dopamin-d3- rezeptors
ATE373665T1 (de) Benzo-kondensierte heteroarylamid-derivative von thienopyridinen nützlich als therapeutische agentien, entsprechende pharmazeutische zusammensetzungen, und methoden für ihre verwendung
DE60336901D1 (de) Chinazolinon modulatoren von nukleinrezeptoren
ATE367381T1 (de) Neue spirotricyclische derivate und deren verwendung als phosphodiesterase-7-inhibitoren
ATE323713T1 (de) Neue heterocyclische fluorglykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
ATE432924T1 (de) 3-aminoindazole derivate und ihre verwendung zur behandlung sgk-bedingten krankheiten
DE602004016992D1 (de) 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3-carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen
ATE460166T1 (de) Chinazolinderivate und ihre verwendung bei der behandlung von thrombocythämie
DE602004010426D1 (de) Mikrobizide zusammensetzungen und ihre verwendung
DE602006010400D1 (de) Olanzapin-analoga und verfahren zu ihrer verwendung
ATE458728T1 (de) 2-(pyridin-2-yl)-pyrimidine und ihre verwendung zur bekämpfung von schadpilzen
DE60214542D1 (de) Verwendung von cox2 inhibitoren zur behandlung von schizophrenia und des ticks
AU2003299945A1 (en) Closed loop control system for pavement surfacing
ATE438395T1 (de) Pyrazolderivate und ihre verwendung als orexin- rezeptor-antagonisten
ATE399776T1 (de) Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors
DE602005022686D1 (de) Einpressmörtelmischung zur verwendung bei einer spannbetonkonstruktion
DE60322052D1 (de) N-acylaminoacetonitril-derivate und ihre verwendung zur kontrolle von parasiten
ATE242223T1 (de) Kondensierte azolderivate und ihre verwendung zur senkung des blutzuckerspiegels

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: BAYER SCHERING PHARMA AG, 13353 BERLIN, DE

8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: BAYER SCHERING PHARMA AKIENGESELLSCHAFT, 13353, DE

8339 Ceased/non-payment of the annual fee